Prostate Cancer International is
for 2011 by Great NonProfits
Perspective Confidentiality Disclosure Reliability Courtesy
The issue of whether to remove the “cancer” word from the diagnosis of at least some forms of prostate pathology that are not likely to lead to clinically significant disease over an extended period of time is not new.
Filed under: Diagnosis, Risk | Tagged: "prostatic epithelial neoplasia", low risk, pathology, PEN | 7 Comments »
In recommendations made in association with a newly published study of the pathologiocal implications of “cribriform” prostate cancer tumors, Dr. Scott Lucia and colleagues are suggesting that all such tumors should be classified as Gleason grade 4 by definition.
Filed under: Diagnosis, Management, Risk | Tagged: cribriform, Gleason, pathology, pattern | 1 Comment »
An interesting new report from the research team at Memorial Sloan-Kettering Cancer Center has explored the relationship between the patterns of occurrence of positive lymph nodes (LNs) and the topography of the cancer in the prostate and the seminal vesicles.
Filed under: Management, Treatment | Tagged: lymph nodes, pathology, pattern, topography, tumor | Leave a Comment »
A new study by a French research team has suggested that there may be a prognostic relationship between the pretreatment testosterone (T) level and the post-surgical pathology of men who undergo radical prostatectomy (RP) for treatment of localized prostate cancer.
Filed under: Diagnosis, Management, Risk, Treatment | Tagged: pathology, radical prostatectomy, T, testosterone | 2 Comments »
Relatively few data have been published on the pathological outcomes of patients initially diagnosed with atypical small acinar proliferation (ASAP), i.e., atypical glands suspicious but not diagnostic for prostate cancer, who are diagnosed with prostate cancer on re-biopsy and then treated by radical prostatectomy.
Filed under: Diagnosis, Living with Prostate Cancer, Management, Treatment | Tagged: ASAP, Diagnosis, pathology, radical prostatectomy, RP | Leave a Comment »
New data from a research group at the University of California provides insight regarding the immediate, relative, pathological outcomes of men undergoing radical prostatectomy (RP) after a period of active surveillance (AS) as compared to those of a similar risk group who received surgery within 6 months of their diagnosis.
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: active surveillance, outcome, pathology, radical prostatectomy | 1 Comment »
One of the unknown factors in the use of high-intensity focused ultrasound (HIFU) for the first-line treatment of prostate cancer is the potential for high-quality, biochemical recurrence-free survival over time. Post-treatment histopathology may offer some insight into the likelihood of good outcomes.
Filed under: Management, Treatment | Tagged: HIFU, high-intensity focused ultrasound, histopathology, pathology | 9 Comments »
A paper from an Australian pathology group has suggested that, “Any proportion of ductal adenocarcinoma in radical prostatectomy specimens predicts extraprostatic extension.”
Filed under: Diagnosis, Management, Risk | Tagged: carcinoma, ductal, pathology, risk | Leave a Comment »
With the increasing acceptance of active surveillance as a management strategy for men initially diagnosed with low-risk prostate cancer, it is increasingly important to have a detailed understanding of how these men fare over time, most particularly among those who have subequent progression that needs treatment.
Filed under: Management, Treatment | Tagged: active surveillance, pathology, radical prostatectomy | Leave a Comment »
Today’s news reports address issues such as: Pro-PSA (a pecursor molecule to PSA itself) A review of development-stage markers for prostate cancer detection Understanding the pathology report A Phase I trial of high-dose testosterone in men with metatstatic CRPC
Filed under: Diagnosis, Management, Risk, Treatment | Tagged: atypia, detection, markers, pathology, pro-PSA, risk, testosterone therapy | Leave a Comment »
FRET stands for “fluorescence resonance-energy transfer.” It’s a way to assess interactions between individual protein molecules, and allows researchers to find out how many receptors of specific types there are in a specific cancer specimen as well as how active those receptors are.
Filed under: Diagnosis, Risk, Uncategorized | Tagged: classification, FRET, pathology | Leave a Comment »
Comment on an article on PSA velocity and prediction of biopsy outcomes has been provided separately. Today’s other news includes reports on: Pathological outcomes and criteria for active surveillance protocols Outcomes to permanent seed implant brachytherapy: age does not affect outcome Vacuum erectile devices and their value in post-prostatectomy erectile dysfunction Biochemical recurrence post-prostatectomy and [...]
Filed under: Diagnosis, Management, Risk, Treatment | Tagged: active surveillance, age, biochemical recurrence, brachytherapy, hormone therapy, outcomes, pathology, vacuum erectile devices, VED | Leave a Comment »
We have separately discussed the recent UK study on sexual activity, age, and prostate cancer risk as well as the results of a Spanish group on radical prostatectomy in patients with Gleason 8-10 at biopsy. In other news today …
Filed under: Uncategorized | Tagged: biopsy, cores, EBRT, lymph nodes, outcomes, pathology, prognosis | Leave a Comment »
Search for new and
ongoing trials on the
CTAG PCa web site